LTF and COVID-19: An almost equal number of patients with COVID-19 in each group were transferred to the ICU or died during hospitalization—24/113 (21.2%) lactoferrin-treated patients vs. 21/105 (20.0%) patients in the placebo group; proportion difference = 1.20% (95% CI: −9.63–11.85), p = 0.8272; RR: 1.06 (95% CI: 0.63–1.79)—clearly indicating that lactoferrin is not effective in modifying the predefined negative composite event rate.